<!DOCTYPE html>
<html lang="en">
  <head>
    <meta charset="UTF-8" />
    <meta http-equiv="X-UA-Compatible" content="IE=edge" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <title>AEMT Medications</title>
    <link rel="stylesheet" href="style.css" />
  </head>
  <body>
    <table class="dark round">
      <thead>
        <th colspan="2" class="header">10 Medication Rights</th>
      </thead>
      <tr>
        <td>Right Patient</td>
        <td>Right Medication</td>
      </tr>
      <tr>
        <td>Right Dose</td>
        <td>Right Route</td>
      </tr>
      <tr>
        <td>Right Time</td>
        <td>Right Documentation</td>
      </tr>
      <tr>
        <td>Right Assessment</td>
        <td>Right to Refuse</td>
      </tr>
      <tr>
        <td>Right Evaluation</td>
        <td>Right Patient Education</td>
      </tr>
    </table>
    <table class="dark round vertical">
      <thead>
        <th colspan="2" class="header">Components of Drug Profile</th>
      </thead>
      <tr>
        <td>Drug names</td>
        <td>Generic name, trade name, and checmical name</td>
      </tr>
      <tr>
        <td>Classification</td>
        <td>What type of drug is this? What is is used for?</td>
      </tr>
      <tr>
        <td>Mechanisms of action</td>
        <td>How does the drug work? What is its intended purpose?</td>
      </tr>
      <tr>
        <td>Indications</td>
        <td>What are the reasons for taking this drug?</td>
      </tr>
      <tr>
        <td>Contraindications</td>
        <td>
          When should the drug not be given? Does it affect certain medical
          conditions or react with other medications adversely?
        </td>
      </tr>
      <tr>
        <td>Pharmacokinetics</td>
        <td>
          How is the drug absorbed, metabolized, and so forth? What is its
          <strong>half-life</strong>
        </td>
      </tr>
      <tr>
        <td>Side and adverse effects</td>
        <td>Are there any side effects? What are the adverse effects?</td>
      </tr>
      <tr>
        <td>Routes of administration</td>
        <td>How is the drug given?</td>
      </tr>
      <tr>
        <td>Supply</td>
        <td>What is the total quantitiy of the medication? What form?</td>
      </tr>
      <tr>
        <td>Dosages</td>
        <td>
          This generally includes proper dosages for adult, pediatric, and
          special considerations, such as when to modify the dosage based on the
          patient's history
        </td>
      </tr>
      <tr>
        <td>Special considerations</td>
        <td>
          There are considerations for certain groups such as pediatric,
          geriatric, and pregnant patients and other special patient groups
        </td>
      </tr>
      <tr>
        <td>Other</td>
        <td>
          The drug profile may include any other information that is vital to
          the user
        </td>
      </tr>
    </table>
    <table class="dark round vertical">
      <thead>
        <th colspan="2" class="header">Albuterol (Proventil, Ventolin)</th>
      </thead>
      <tr>
        <td>Class</td>
        <td>Sympathomimetic, bronchodilator</td>
      </tr>
      <tr>
        <td>Mechanism of action</td>
        <td>
          Selective beta-2 agonist that stimulates adrenergic receptors of the
          sympathomimetic nervous system causing smooth muscle relaxation in the
          bronchial tree and peripheral vasculature
        </td>
      </tr>
      <tr>
        <td>Indications</td>
        <td>
          Treatment of bronchospasm in patients with reversible obstructive
          airway disease (COPD/Asthma). Prevention of exercise-induced
          bronchospasm
        </td>
      </tr>
      <tr>
        <td>Contraindications</td>
        <td>
          Hypersensitivity. Tachycardia, dysrhythmias, especially caused by
          digitalis. Synergistic with otehr sympathomimetics
        </td>
      </tr>
      <tr>
        <td>Adverse reactions/side effects</td>
        <td>
          Headache, fatigue, light-headedness, irritability, restlessness,
          aggressive behavior, pulmonary edema, hoarseness, nasal congestion,
          increased sputum, hypertension, tachycardia, dysrhythmias, chest pain,
          palpitations, nausea/vomiting, dry mouth, epigastric pain, and tremors
        </td>
      </tr>
      <tr>
        <td>Drug inertactions</td>
        <td>
          Tricyclic antidepressants may potentiate vasculature effects. Beta
          blockers are antogonistic and may block pulmonary effects. May
          pontentiate hypokalemia caused by diuretics
        </td>
      </tr>
      <tr>
        <td>Route</td>
        <td>Inhalation (Nebulizer or MDI)</td>
      </tr>
      <tr>
        <td>Dosage and Administration</td>
        <td>
          <b>Adult:</b> Administer 2.5mg in 3mL of normal saline and administer
          over 10 to 15 minutes. <b>MDI:</b> 1-2 inhalations (90mcg per
          inhalation)<br /><b>Pediatric</b>: Less than 20kg: 1.25 mg/dose via
          nebulizer or mask over 20 minutes; Greater than 20kg: 2.5mg/dose via
          nebulizer or mask over 20 minutes. Repeat once in 20 minutes.
        </td>
      </tr>
      <tr>
        <td>Duration of Action</td>
        <td>
          <b>Onset:</b> 5 to 15 minutes<br /><b>Peak effect:</b> 30 minutes to 2
          hours<br /><b>Duration:</b> 3 to 4 hours
        </td>
      </tr>
      <tr>
        <td>Special Considerations</td>
        <td>
          Pregnancy safety: Category C. May precipitate angina pectoris and
          dysrhythmias. Inhalation only. Patients may need to be coached on
          proper use of MDI, particularly with spacer
        </td>
      </tr>
    </table>
    <table class="dark round vertical">
      <thead>
        <th colspan="2" class="header">Aspirin (Acetylsalicylic Acid)</th>
      </thead>
      <tr>
        <td>Class</td>
        <td>Pletelet inhibitor, anti-inflammatory agent</td>
      </tr>
      <tr>
        <td>Mechanism of Action</td>
        <td>
          Prevents the formation of thromboxane, which causes platelets to clump
          together (aggregate) and form plugs that cause obstruciton or
          constriction; has antipyretic (to reduce fever) and analgesic (to
          relieve pain) properties
        </td>
      </tr>
      <tr>
        <td>Indications</td>
        <td>New onset chest discomfort that suggests ACS</td>
      </tr>
      <tr>
        <td>Contraindications</td>
        <td>Hypersensitivity<br />Active ulcer disease<br />Asthma</td>
      </tr>
      <tr>
        <td>Adverse reactions/side effects</td>
        <td>
          Bronchospasm, anaphylaxis, wheezing in allergic patients, prolonged
          bleeding, GI bleeding, epigastric distress, nausea/vomiting,
          heartburn, Reye syndrome
        </td>
      </tr>
      <tr>
        <td>Drug interactions</td>
        <td>Use with caution in patients allergic to NSAIDs</td>
      </tr>
      <tr>
        <td>Route</td>
        <td>Oral (chewable tablets)</td>
      </tr>
      <tr>
        <td>Dosage and administration</td>
        <td>
          <b>Adult:</b> 160 to 325mg PO. Chewing is preferred to swallowing<br /><b
            >Pediatric:</b
          >
          Not recommended
        </td>
      </tr>
      <tr>
        <td>Duration of action</td>
        <td>
          <b>Onset:</b> 5 to 30 minutes<br /><b>Peak effect:</b> 1 to 3 hours<br /><b
            >Duration:</b
          >
          3 to 6 hours
        </td>
      </tr>
      <tr>
        <td>Special considers</td>
        <td>
          Pregnancy Category D. Should be given to all patients that present
          wtih ACS (Acute Coronary Syndrome). Not recommended in pediatric
          populations
        </td>
      </tr>
    </table>
    <table class="dark round vertical">
      <thead>
        <th colspan="2" class="header">Dextrose</th>
      </thead>
      <tr>
        <td>Class</td>
        <td>Carbohydrate, antihypoglycemic, hypertonic solution</td>
      </tr>
      <tr>
        <td>Mechanism of Action</td>
        <td>Rapidly increases glucose levels. Short-term osmotic diuresis</td>
      </tr>
      <tr>
        <td>Indications</td>
        <td>
          Hypoglycemia, altered level of conciousness, coma of unknown orgin,
          seizure of unknown orgin, status epilepticus
        </td>
      </tr>
      <tr>
        <td>Contraindications</td>
        <td>Intracranial hemorrhage with normal blood glucose level</td>
      </tr>
      <tr>
        <td>Adverse reactions/side effects</td>
        <td>
          Extravasation leads to tissue necrosis (mainly due to acidity).
          Cerebral hemorrhage; cerebral ischemia; pulmonary edema, warmth, pain,
          burning from IV infusion, hyperglycemia
        </td>
      </tr>
      <tr>
        <td>Drug interactions</td>
        <td>Sodium bicarbonate, wafarin (Coumadin)</td>
      </tr>
      <tr>
        <td>Route</td>
        <td>IV, IO</td>
      </tr>
      <tr>
        <td>Dosage and Administration</td>
        <td>
          <b>Adult:</b> D<sub>50</sub> 25g slow IV push. Another option is D<sup
            >10</sup
          >
          can be as effective as D<sup>50</sup> and D<sup>25</sup><br /><b
            >Pediatric:</b
          >
          1 year and older: D<sup>25</sup> 0.5 - 1 g/kg/dose<br /><b
            >Neonates and Infants:</b
          >
          D<sup>10</sup> 200 - 500 mg/kg. Maximum concentration of 12.5% due to
          vasculature sensitivity
        </td>
      </tr>
      <tr>
        <td>Duration of Action</td>
        <td>
          <b>Onset:</b> Less than 1 minute<br /><b>Peak effect:</b>
          Variable<br /><b>Duration:</b> Variable
        </td>
      </tr>
      <tr>
        <td>Special Considerations</td>
        <td>
          Pregnancy category C. Draw blood to determine glucose level before
          administering. DO NOT administer to patients with known CVA unless
          hypoglycemia documented. Due to shortages it may not be avaliable in
          bolus form
        </td>
      </tr>
    </table>
    <table class="dark round vertical">
      <thead>
        <th colspan="2" class="header">
          Epinephrine (Adrenalin) 1mg/mL (1:1,000)
        </th>
      </thead>
      <tr>
        <td>Class</td>
        <td>Sympathomimetic</td>
      </tr>
      <tr>
        <td>Mechanism of Action</td>
        <td>
          α: vasoconstriction<br />β<sub>1</sub>: Positive inotropic (increases
          contractility), chronotropic (increases rate), dromotropic (increases
          conduction speed)<br />β<sub>2</sub>: Bronchial smooth muscle
          relaxation and dilation of skeletal vasculature. Blocks histamine
          receptors
        </td>
      </tr>
      <tr>
        <td>Indications</td>
        <td>Allergic reaction, anaphylaxis, asthma</td>
      </tr>
      <tr>
        <td>Contraindications</td>
        <td>
          None in an emergency setting. However relative contraindications are
          hypertension, hypothermia, pulmonary edema, myocardial ischemia,
          hypovolemic shock
        </td>
      </tr>
      <tr>
        <td>Adverse reactions/side effects</td>
        <td>
          Nervousness, restlessness, headache, tremor, pulmonary edema,
          dysrhythmias, chest pain, hypertension, tachycardia, nausea/vomiting
        </td>
      </tr>
      <tr>
        <td>Drug Interations</td>
        <td>
          Pottentiates other sympathomimetics; MAOIs may potentiate effects. β
          blockers may blunt effect
        </td>
      </tr>
      <tr>
        <td>Routes</td>
        <td>IM, subcutaneous</td>
      </tr>
      <tr>
        <td>Dosage and Administration</td>
        <td>
          <b>Adult:</b> 0.3 - 0.5mg (generally stocked in 1mg/mL)<br /><b
            >Pediatric:</b
          >
          0.01mg/kg (maximum dose of 0.3mg
        </td>
      </tr>
      <tr>
        <td>Duration of Action</td>
        <td>
          <b>Onset:</b> Immediate<br /><b>Peak effect:</b> Minutes<br /><b
            >Duration:</b
          >
          Several minutes
        </td>
      </tr>
      <tr>
        <td>Special Considerations</td>
        <td>
          Pregnancy category C. May cause syncope in asthmatic children. May
          increase myocardial oxygen demand
        </td>
      </tr>
    </table>
    <table class="dark round vertical">
      <thead>
        <th colspan="2" class="header">Glucagon (GlucaGen)</th>
      </thead>
      <tr>
        <td>Class</td>
        <td>Hyperglycemia agent, pancreatic hormone, insulin antagonist</td>
      </tr>
      <tr>
        <td>Mechanism of Action</td>
        <td>
          Increases blood glucose level by stimulating glycogenesis. Unknown
          mechanism of stablizing cardiac rhythm in beta blocker overdose.
          Minimal positive inotropic and chronotropic response. Decreases GI
          motility and secretions
        </td>
      </tr>
      <tr>
        <td>Indications</td>
        <td>
          Altered level of consciousness when hypoglycemia is suspected. May be
          used as a reversal agent in beta blocker overdose
        </td>
      </tr>
      <tr>
        <td>Contraindication</td>
        <td>Hyperglycemia, hypersensitivity</td>
      </tr>
      <tr>
        <td>Adverse reactions/side effects</td>
        <td>
          incompatible in solution with most other substances. No significant
          drug interactions with other emergency medications
        </td>
      </tr>
      <tr>
        <td>Route</td>
        <td>IM</td>
      </tr>
      <tr>
        <td>Dosage and Administration</td>
        <td>
          <b>Adult:</b> 1mg IM; may repeat in 7 in 10 minutes<br /><b
            >Pediatric:</b
          >
          1mg if 20kg (44lbs) or greater or 5 years or more; 0.5mg IM if less
          than 20kg (44lbs) or younger than 5 years
        </td>
      </tr>
      <tr>
        <td>Duration of Action</td>
        <td>
          <b>Onset:</b> 1 minute<br /><b>Peak effect:</b> 5 - 20 minutes<br /><b
            >Duration:</b
          >
          60 - 90 minutes
        </td>
      </tr>
      <tr>
        <td>Special Considerations</td>
        <td>
          Pregnancy category B. Should be used in conjunction with
          D<sub>50</sub>. If patient does not respond to a second dose of
          glucagon, D<sub>50</sub> must be adminstered. Requires reconstitution
          with supplied solution
        </td>
      </tr>
    </table>
    <table class="dark round vertical">
      <thead>
        <th colspan="2" class="header">Naloxone Hydrochloride (Narcan)</th>
      </thead>
      <tr>
        <td>Class</td>
        <td>Opioid antagonist, antidoe</td>
      </tr>
      <tr>
        <td>Mechanism of Action</td>
        <td>
          Competitive inhibition at narcotic receptor sites. Reverses
          respiratory depression secondary to opiate drugs. Completely inhibits
          the effect of morphine
        </td>
      </tr>
      <tr>
        <td>Indications</td>
        <td>
          Opiate overdose, complete or partial reversal of CNS and respiratory
          depression induced by opiods, decreases level of consciousness, coma
          of unknown orgin.<br />Narcotic agonist for the following: morphine
          sulfate, heroin, HYDROmorphone (Dilaudid), methadone, meperidine
          (Demerol), paregoric, fentaNYL (Sublimaze), oxycodone (Percodan),
          codeine, propoxyphene (Darvon).<br />Narcotic agonist and antagonist
          for the following: butorphanol (Stadol), pentazocine (Talwin),
          nalbuphine (Nubain)
        </td>
      </tr>
      <tr>
        <td>Contraindications</td>
        <td>
          Use with caution in narcotic-dependent patients. Use with caution in
          neonates of narcotic-addicted mothers
        </td>
      </tr>
      <tr>
        <td>Adverse reactions/side effects</td>
        <td>
          Restlessness, seizures, dyspnea, pulmonary edema, tachycardia,
          hypertension, dysrhythmias, nausea/vomiting, withdrawal symptoms in
          opiod-addicted patients, diaphoresis
        </td>
      </tr>
      <tr>
        <td>Drug Interactions</td>
        <td>Incompatible with bisulfite and alkaline solutions</td>
      </tr>
      <tr>
        <td>Route</td>
        <td>IV, IN, IO, IM (auto-injector)</td>
      </tr>
      <tr>
        <td>Dosage and Administration</td>
        <td>
          <b>Adult:</b> 0.4 - 2.0mg IM/IV/IO; Repeat at 5 minute intervals to a
          total maximum dose of 10mg. For IN route, administer one half of the
          dose in each nostril; maximum dose is 1mL per nostril<br /><b
            >Pediatric:</b
          >
          0.1mg/kg/dose IV/IO/IM every 2 minutes as needed. Maximum total dose
          of 2mg. If no response in 10 minutes administer an additional
          0.1mg/kg/dose
        </td>
      </tr>
      <tr>
        <td>Duration of Action</td>
        <td>
          <b>Onset:</b> Less than 2 minutes<br /><b>Peak effect:</b>
          Variable<br /><b>Duration:</b> 30 - 60 minutes
        </td>
      </tr>
      <tr>
        <td>Special Considerations</td>
        <td>
          Pregnancy category C. Assist ventilation prior to administration to
          avoid sympathetic stimulation. Seizures without causal relationship
          have been reported. May not reverse hypotension. Use caution for
          potential violent behavior. Half-life of naloxone is shorter than the
          half-life of narcotics so repeat doses may be required. In cardiac
          arrest, naloxone is generally not beneficial
        </td>
      </tr>
    </table>
  </body>
</html>
